Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

被引：1

作者：

Yoroidaka, Takeshi ^{[1
,2
]}

Takamatsu, Hiroyuki ^{[1
]}

Yamashita, Takeshi ^{[3
]}

Murata, Ryoichi ^{[3
]}

Yoshihara, Kyoko ^{[4
]}

Yoshihara, Satoshi ^{[4
]}

Ueda, Mikio ^{[3
]}

Nakao, Shinji ^{[1
]}

Matsue, Kosei ^{[5
]}

机构：

[1] Kanazawa Univ, Dept Hematol, Kanazawa, Ishikawa, Japan

[2] Keiju Med Ctr, Dept Internal Med, Nanao, Japan

[3] Keiju Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa, Japan

[4] Hyogo Coll Med, Dept Hematol, Nishinomiya, Hyogo, Japan

[5] Kameda Med Ctr, Div Hematol Oncol, Dept Med, Kamogawa, Japan

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126552

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3130

引用

页数：3

共 50 条

[21] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Korde, Neha
Derkach, Andriy
Hultcrantz, Malin
Maclachlan, Kylee H.
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Lesokhin, Alexander
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Hofmeister, Craig C.
Kaufman, Jonathan L.
Nooka, Ajay K.
Usmani, Saad Z.
Lonial, Sagar
Joseph, Nisha S.
BLOOD, 2023, 142
[22] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Maria Gavriatopoulou
Evangelos Terpos
Ioannis Ntanasis-Stathopoulos
Panagiotis Malandrakis
Evangelos Eleutherakis-Papaiakovou
Athanasios Papatheodorou
Nikolaos Kanellias
Magdalini Migkou
Despina Fotiou
Ioanna Dialoupi
Maria Roussou
Nikoletta-Aikaterini Kokkali
Efstathios Kastritis
Meletios A. Dimopoulos
Blood Cancer Journal, 10
[23] Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
Gavriatopoulou, Maria
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Eleutherakis-Papaiakovou, Evangelos
Papatheodorou, Athanasios
Kanellias, Nikolaos
Migkou, Magdalini
Fotiou, Despina
Dialoupi, Ioanna
Roussou, Maria
Kokkali, Nikoletta-Aikaterini
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD CANCER JOURNAL, 2020, 10 (03)
[24] Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma
Nishant Tageja
Neha Korde
Dickran Kazandjian
Sandhya Panch
Elisabet Manasanch
Manisha Bhutani
Mary Kwok
Sham Mailankody
Constance Yuan
Maryalice Stetler-Stevenson
Susan F. Leitman
Claude Sportes
Ola Landgren
Bone Marrow Transplantation, 2018, 53 : 1445 - 1449
[25] Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma
Tageja, Nishant
Korde, Neha
Kazandjian, Dickran
Panch, Sandhya
Manasanch, Elisabet
Bhutani, Manisha
Kwok, Mary
Mailankody, Sham
Yuan, Constance
Stetler-Stevenson, Maryalice
Leitman, Susan F.
Sportes, Claude
Landgren, Ola
BONE MARROW TRANSPLANTATION, 2018, 53 (11) : 1445 - 1449
[26] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
Tan, Carlyn
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Patel, Dhwani
Maclachlan, Kylee H.
Lahoud, Oscar B.
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander M.
Korde, Neha
Usmani, Saad
BLOOD, 2022, 140 : 1817 - 1819
[27] A REAL-WORLD EFFICACY AND SAFETY ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) COMBINATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Caratozzolo, I.
Tacchetti, P.
Zambello, R.
Pantani, L.
Antonioli, E.
Mancuso, K.
Buda, G.
Rocchi, S.
Canepa, L.
Rizzello, I.
Gamberi, B.
Barila, G.
Testoni, N.
Marzocchi, G.
Zamagni, E.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 66 - 66
[28] A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
Bhutani, Manisha
Foureau, David M.
Robinson, Myra
Guo, Fei
Fesenkova, Kateryna
Atrash, Shebli
Paul, Barry
Varga, Cindy
Friend, Reed
Pineda-Roman, Mauricio
Rigby, Katherine
Symanowski, James T.
Norek, Sarah
Tucker, Mallory R.
Druhan, Lawrence J.
Voorhees, Peter M.
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 535 - +
[29] Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone
Costa, Luciano J.
Burwick, Nicholas
Jakubowiak, Andrzej
Kaufman, Jonathan L.
Cabanillas, Fernando
Dail, Monique
Karve, Sudeep
Masud, Abdullah A.
Yang, Xiaoqing
Bueno, Orlando F.
Mudd, Sarah
Ross, Jeremy A.
Davies, Faith E.
BLOOD, 2020, 136
[30] Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
Piedra, Katrina
Peterson, Tim
Tan, Carlyn
Orozco, Jennifer
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Lesokhin, Alexander
Shah, Urvi
Lu, Sydney
Patel, Dhwani
Derkach, Andriy
Wilkins, Cy R.
Korde, Neha
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 105 - 109

← 1 2 3 4 5 →